Navigation Links
New target for heart failure therapy identified
Date:3/16/2009

(PHILADELPHIA) A novel signaling pathway plays a significant role in the production of aldosterone, a hormone that promotes heart failure after a myocardial infarction, according to a study conducted by Thomas Jefferson University researchers.

The findings, which will be published online this week in Proceedings of the National Academy of Sciences, show that aldosterone production is mediated by a protein called beta-arrestin-1. Beta-arrestin-1 binds to angiotensin II receptors when they are activated by angiotensin II.

Aldosterone is secreted by the adrenal cortex. Its levels are elevated in chronic heart failure, and its presence contributes to morbidity and mortality of the disease. It contributes to heart failure progression and diminished cardiac function after myocardial infarction.

The production of aldosterone was previously thought to be solely the result of the activation of G-proteins, which are also activated when angiotensin II binds to its receptors, according to Anastasios Lymperopoulos, Ph.D., a Post-Doctoral Research Fellow in the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy at Jefferson Medical College of Thomas Jefferson University.

"The bottom line is that in order to effectively suppress aldosterone production, you need to inhibit beta-arrestin-1 in addition to inhibiting G-proteins," said Dr. Lymperopoulos, who is the lead author of the study.

All the drugs currently available for suppression of aldosterone by angiotensin II primarily target G-protein signaling pathways. However, Walter Koch, Ph.D., the W.W. Smith Professor of Medicine and the Director of the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy, said that these data clearly show that beta-arrestin1 plays a more significant role in aldosterone secretion than G-proteins.

"Aldosterone secretion is dependent on beta-arrestin-1," Dr. Koch said. "It may not be independent of G-proteins, but beta-arrestin-1 is definitely the critical player. The goal should be to find a new antagonist that can block beta-arrestin-1 and G-protein activation equally well. Doing so would lead to lower aldosterone levels at its source and alleviate negative remodeling processes in the injured heart."


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
3. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
4. U.S. Health Initiative Targets Aging Hispanics
5. Global Health Project targets reducing AIDS among Indias adolescents
6. Study suggests brain tumors need treatment with multiple targeted drugs
7. GP targets on heart disease should be simpler and based more on treatment and prevention
8. T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
9. Chronic infection persists by targeting stromal cell network in lymphoid organs
10. Prime Access Creates Groundbreaking Ads Targeting Urban Teens for the White Houses National Youth Anti-Drug Media Campaign
11. International Law Enforcement Operation Targets Underground Manufacture of Anabolic Steroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Wexford, PA (PRWEB) , ... December 02, 2016 , ... ... manages stress and overall health, day and night. No other wearable health technology on ... management. We wanted to give poeple more meaningful insights about their health than ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health Solutions, ... raised $6.0 million in an initial round of funding. The round was led ... their caregivers can receive far better care through the application of the best ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November 28, 2016 ... Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, America’s leading ... Climate Change and Your Health radio program syndicated on Voice of America, welcomed ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge dentists, Dr. ... plan for all patients. Understanding that budget can play a part in oral ... of perks, including discounts on many valuable dental treatments. Options for individuals, couples, ...
(Date:11/30/2016)... Beach Gardens, FL (PRWEB) , ... November 30, ... ... in eating disorder and mental health treatment has announced the opening of a ... provides specialized partial hospitalization and intensive outpatient treatment for adults and adolescents, both ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016   CytoSorbents Corporation (NASDAQ: ... European Union approved CytoSorb ® cytokine adsorber to ... worldwide, announced that Dr. Phillip Chan , Chief ... LD Micro Main Event investor conference held from ... Luxe Sunset Boulevard Hotel in Los Angeles, ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... and Companies" to their offering. ... , , Drug ... market value of drug delivery technologies and the anticancer drugs are ... to organs involved and the types of cancer as well as ...
(Date:12/2/2016)... Around the corners of world, cancer has infused itself ... over earth. Cancer has become one of those nightmares ... this is because of the increasing incidence rates and ... increase in global cancer incidence with its associated morbidity ... treatment, there is increasing interest in this stringent disease. ...
Breaking Medicine Technology: